FDA greenlights Pfizer/Arvinas breast cancer therapy vepdegestrant despite modest trial results

The U.S. Food and Drug Administration announced approval of vepdegestrant, a therapy developed by Pfizer and Arvinas, for a specific subtype of breast cancer.

The decision comes even though the clinical data presented were described as underwhelming, with modest efficacy signals that fell short of expectations.

Analysts note that while the approval adds a new option for patients, the limited data may restrict uptake, and the market impact remains uncertain.